Bioxcel Therapeutics Inc (BTAI)

01:18 AM

BioXcel Therapeutics Initiates At-The-Market Equity Program - Investing.com Australia

01:18 AM

Apr 03, 2025

Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through CanaccordSEC Filing - MarketScreener

Apr 03, 2025

Mar 29, 2025

BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 29, 2025

Mar 29, 2025

BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 29, 2025

Mar 28, 2025

BioXcel Therapeutics Advances Clinical Trials and Reduces Losses - TipRanks

Mar 28, 2025

Mar 28, 2025

BioXcel Therapeutics Inc. (BTAI) reports earnings - Quartz

Mar 28, 2025

Mar 28, 2025

BioXcel Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 28, 2025

Mar 27, 2025

BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

BioXcel Therapeutics, Inc. Q4 Loss Declines - Nasdaq

Mar 27, 2025

Mar 27, 2025

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewswire

Mar 27, 2025

Mar 22, 2025

BioXcel Therapeutics (NASDAQ:BTAI) Upgraded at RODMAN&RENSHAW - Defense World

Mar 22, 2025

Mar 21, 2025

BioXcel Therapeutics faces potential Nasdaq delisting By Investing.com - Investing.com Australia

Mar 21, 2025

Mar 21, 2025

BioXcel Therapeutics faces potential Nasdaq delisting - Investing.com

Mar 21, 2025

Mar 21, 2025

BIOXCEL THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 21, 2025

Mar 21, 2025

BioXcel Therapeutics reports progress in Phase 3 trial By Investing.com - Investing.com South Africa

Mar 21, 2025

Mar 21, 2025

BioXcel Therapeutics reports progress in Phase 3 trial - Investing.com India

Mar 21, 2025

Mar 19, 2025

Rodman & Renshaw Initiates Coverage of BioXcel Therapeutics (BTAI) with Buy Recommendation - Nasdaq

Mar 19, 2025

Mar 19, 2025

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - Nasdaq

Mar 19, 2025

Mar 11, 2025

BioXcel Therapeutics boosts cash to $35M for Phase 3 trial - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

BioXcel Therapeutics boosts cash to $35M for Phase 3 trial By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 11, 2025

BioXcel Therapeutics: Topline Data Expected In H2 Of 2025 To Support Potential SNDA Submission For Label Expansion Of Igalmi In Home Setting - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire

Mar 11, 2025

Mar 11, 2025

BioXcel's $35M Funding Boost Powers Breakthrough At-Home Mental Health Treatment Trial - StockTitan

Mar 11, 2025

Mar 10, 2025

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 10, 2025

Mar 09, 2025

Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week - MSN

Mar 09, 2025

Mar 09, 2025

10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey

Mar 09, 2025

Mar 08, 2025

BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - MSN

Mar 08, 2025

Mar 07, 2025

BioXcel Therapeutics reaches 33% enrollment in trial By Investing.com - Investing.com Australia

Mar 07, 2025

Mar 07, 2025

BioXcel Therapeutics reaches 33% enrollment in trial - Investing.com

Mar 07, 2025

Mar 07, 2025

BioXcel Therapeutics Reports 33% Enrollment in SERENITY At-Home Trial for IGALMI® Label Expansion, Topline Data Expected in 2025 - Nasdaq

Mar 07, 2025

Mar 07, 2025

BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial - TipRanks

Mar 07, 2025

Mar 07, 2025

BioXcel Therapeutics Announces 33% Enrollment in SERENITY - GlobeNewswire

Mar 07, 2025

Mar 07, 2025

Could This Be the First FDA-Approved At-Home Treatment for Bipolar and Schizophrenia Agitation? - StockTitan

Mar 07, 2025

Mar 07, 2025

BioXcel Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 05, 2025

BioXcel Therapeutics raises $14M in direct offering - Hartford Business Journal

Mar 05, 2025

Mar 05, 2025

Building Materials Stocks Q4 In Review: Sherwin-Williams (NYSE:SHW) Vs Peers - The Globe and Mail

Mar 05, 2025

Mar 04, 2025

Top Penny Stocks To Watch NowFebruary 28th - MarketBeat

Mar 04, 2025

Mar 04, 2025

Bioxcel Therapeutics Announces Closing Of $14 Million Registered Direct Offering -March 04, 2025 at 04:50 pm EST - Marketscreener.com

Mar 04, 2025

Mar 04, 2025

BioXcel Therapeutics, Inc. Closes $14 Million Registered Direct Offering of Common Stock and Warrants - Nasdaq

Mar 04, 2025

Mar 04, 2025

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering - GlobeNewswire

Mar 04, 2025

Mar 04, 2025

How Will BioXcel's $14M Offering Impact Shareholders? Key Details on BTAI's Latest Financing - StockTitan

Mar 04, 2025

Mar 04, 2025

3 Penny Stocks to Watch Now, 3/4/25 - TipRanks

Mar 04, 2025

Mar 04, 2025

Stock Market Update – BioXcel Therapeutics Stock Price Prediction 2025 - ldccbank

Mar 04, 2025